Loading
Jon Pilcher

Jon Pilcher

CEO, Neuren Pharmaceuticals
Australia
Jon joined Neuren in August 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.
Sessions

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS